	Utech
Name :	<u>A</u>
Roll No.:	A Day of Your Life 2nd Explana
Invigilator's Signature :	

CS/M.PHARM/SEM-2/MPT-206(1)/2012 2012 DRUG DELIVERY SYSTEM

Time Allotted: 3 Hours Full Marks: 70

The figures in the margin indicate full marks.

Candidates are required to give their answers in their own words as far as practicable.

GROUP - A

(Multiple Choice Type Questions)

1. Choose the correct alternatives for any *ten* of the following :

 $10 \times 1 = 10$


- (i) In transdermal drug delivery, Azones and Pyrrolidones are used as
 - a) channeling agents
 - b) permeation enhancer
 - c) rate controlling polymers
 - d) all of these.
- (ii) Drug targeting to intracellular sites is also known as
 - a) Primary Targeting b) Secondary Targeting
 - c) Tertiary Targeting d) None of these.

30424(M.PHARM)

[Turn over

CS/M.PHARM/SEM-2/MPT-206(1)/2012

- (iii) Tissue rejection may be avoided for implantable drug delivery systems by incorporating
 - a) Heparin
- b) Insulin
- c) Glucocorticoids
- d) Eicosanoids.
- (iv) NLCs, Dissocubes and SLNs are examples of
 - a) Polymeric nanoparticles
 - b) liposomal dispersions
 - c) surfactant aggregates
 - d) lipid nanoparticles.
- v) Higuchi's square root equation is modified for heterogeneous matrices by incorporating the term
 - a) tortuosity/porosity
- b) porosity/density
- c) porosity/tortuosity
- d) density/porosity.
- vi) Drug Eluting Stents are examples of
 - a) site specific drug delivery systems
 - b) localized drug delivery systems
 - c) implantable drug delivery systems
 - d) targeted drug delivery systems.



vii) Keshary-Chien apparatus may be used to evaluate drug release from

- a) Microparticles
- b) Nanocapsules
- c) Transdermal devices
- d) Osmotic pumps.

viii) The concept of chronopharmaceutics is based on

- a) Repeat release
- b) Circadian Rhythm
- c) Both of these
- d) None of these.
- ix) Which of the following is true for Fick's first law of diffusion?
 - a) Refers to the non steady-state flow
 - b) The amount of material flowing through a unit cross-section of a barrier in unit time is known as the concentration gradient
 - c) Flux of material is proportional to the concentration gradient
 - d) Diffusion occurs in the direction of increasing concentration.

CS/M.PHARM/SEM-2/MPT-206(1)/2012

- x) Which equation describes the rate of drug dissolution from a tablet?
 - a) Fick's law
 - b) Henderson-Hasselbalch equation
 - c) Michaelis-Menten equation
 - d) Noyes-Whitney equation.
- xi) Dose-dumping in controlled release formulation causes
 - a) sustained action
- b) increased toxicity
- c) slowing of action
- d) increased metabolism
- xii) Tortuosity and porosity consideration is relevant in
 - a) drug release by diffusion
 - b) drug release by dissolution
 - c) drug release by erosion
 - d) none of these.


GROUP - B

(Short Answer Type Questions)

Answer any *three* of the following. $3 \times 5 = 15$

- 2. Explain various types of Transdermal therapeutic systems with suitable diagrams.
- 3. Write a short note on permeation enhancers in transdermal delivery.

30424(M.PHARM)



- 4. What are Nanoparticles? Discuss their application as novel delivery systems.
- 5. Classify implantable drug delivery systems. Briefly explain their limitations.
- 6. Write a note on Elementary osmotic pump.
- 7. Describe the kinetics of drug release from Microreservoir-Dissolution-Controlled drug delivery system.

GROUP - C

(Long Answer Type Questions)

Answer any *three* of the following. $3 \times 15 = 45$

- 8. a) Discuss the problems encountered in delivery of therapeutic proteins and peptides.
 - b) Add a note on non-invasive means of protein delivery.

10 + 5


CS/M.PHARM/SEM-2/MPT-206(1)/2012



- 9. a) Enlist various drug targeting strategies.
 - b) Explain in details the brain specific drug delivery systems. $5+10 \label{eq:5}$
- 10. a) Briefly discuss the various pharmacokinetic considerations in design of CR drug delivery systems.
 - b) Assuming a one-compartment disposition, explain and derive the expressions for determining the zero-order drug delivery rate for a sustained release system.

$$7\frac{1}{2} + 7\frac{1}{2}$$

- 11. a) Discuss the special status of liposomes in novel drug delivery.
 - b) Mention with suitable explanations the limitations of liposomes.



- 12. a) Classify the Bio-adhesive polymers with suitable example of each class.
 - b) What are the factors affecting the mucoadhesion?

7 + 8

- 13. a) What is the mechanism and drug release kinetics from Matrix Diffusion Controlled drug delivery system?
 - b) Give an example of such system with fabrication technique and diagram.
 - c) Discuss in brief about the theories of Bio-adhesion.

6 + 5 + 4